

INTERNATIONAL BREAST CANCER STUDY GROUP; TRANSLATIONAL RESEARCH

1. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Öhlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS for the International Breast Cancer Study Group (IBCSG): Chemo-endocrine versus endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors. *J Clin Oncol*, in press. (Trials VIII-IX)
2. Viale G, Regan MM, Mastropasqua MG, Maiorano E, Maffini F, Colleoni M, Price KN, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Öhlschlegel C, Gusterson B, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Coates AS, for the IBCSG. Value of Ki67 in two randomized trials of chemo-endocrine therapies for node-negative breast cancer. Submitted. (Trials VIII-IX)
3. Ravaioli A, Monti F, Regan MM, Maffini F, Mastropasqua MG, Spataro V, Panzini I, Gianni L, Goldhirsch A, Viale G. p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. Submitted. (Trials VIII-IX)
4. Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G for the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Centrally assessed HER2 status in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal women with early breast cancer: results from study BIG 1-98. Submitted.
5. Viale G, Giobbie-Hurder A, for the BIG 1-98 Collaborative and International Breast Cancer Study Groups. Value of centrally-assessed Ki-67 labeling index as a marker of prognosis and predictor of response to adjuvant endocrine therapy in the BIG 1-98 Trial of postmenopausal women with estrogen receptor-positive breast cancer. Accepted for oral presentation, San Antonio Breast Cancer Symposium, 2007. (BIG 1-98)
6. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Oehlschlegel C, Thürlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal women with early breast cancer: BIG 1-98. *J Clin Oncol*, 25:3846-3852, 2007. (BIG 1-98)
7. Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A, Brown B, Suurküla M, Langman G, Mazzucchelli L, Braye S, Grigolato P, Gelber RD, Castiglione-Gertsch M, Price KN, Coates AS, Goldhirsch A, Gusterson B for the IBCSG. Re-evaluating adjuvant breast cancer trials: Assessing hormone receptor status by immunohistochemical versus extraction assays. *J Natl Cancer Inst* 98:1571-1581, 2006. (Trials VIII-IX)
8. Spataro VJ, Litman H, Viale G, Maffini F, Masullo M, Golouh R, Martinez-Tello FJ, Grigolato P, Shilkin KB, Gusterson BA, Castiglione-Gertsch M, Price K, Lindtner J, Cortés-Funes H, Simoncini E, Byrne MJ, Collins J, Gelber RD, Coates AS, Goldhirsch A. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: Results from International Breast Cancer Study Group Trial V. *Cancer* 97:1591-1600, 2003. (Trial V)
9. Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch M, Gusterson BA. Ki-67 expression in breast carcinoma: Its association with grading systems, clinical parameters, and other prognostic factors - A surrogate marker? *Cancer* 97:1321-1331, 2003. (Trial V)
10. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderbergh J, Anbazhagan R, Styles K, Rudenstam C-M, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Bürki K, Castiglione M, Collins J, Lindtner J, Senn HJ, for the International Breast Cancer Study Group: Prognostic importance of c-erbB-2 expression in breast cancer. *J Clin Oncol/Classic Papers and Current Comments* 5:908-916, 2001. (Trial V)
11. Pinder SE, Murray S, Ellis IO, Trihia H, Elston CW, Gelber RD, Goldhirsch A, Lindtner J, Cortés-Funes H, Simoncini E, Byrne MJ, Golouh R, Rudenstam CM, Castiglione-Gertsch M, Gusterson BA. The importance of histological grade in invasive breast carcinoma and response to chemotherapy. *Cancer* 83:1529-1539, 1998. (Trial V)
12. Pestalozzi BC, Peterson HF, Gelber RD, Goldhirsch A, Gusterson BA, Lindtner J, Cortés-Funes H, Simoncini E, Byrne MJ, Golouh R, Rudenstam C-M, Castiglione-Gertsch M, Allegra CJ, Johnston PG. The prognostic importance of Thymidylate Synthase expression in early breast cancer. *J Clin Oncol* 15:1923-1931, 1997. (Trial V)
13. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderbergh J, Anbazhagan R, Styles K, Rudenstam C-M, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Bürki K, Castiglione M, Collins J, Lindtner J, Senn HJ for the International Breast Cancer Study Group: Prognostic

- importance of c-erbB-2 expression in breast cancer. *Classic Papers and Current Comments* 1:32-40, 1996. (Trial V)
14. Nathan B, Gusterson B, Jadayel D, O'Hare M, Anbazhagan R, Jayatilake H, Ebbs S, Micklem K, Price K, Gelber R, Reed R, Senn H-J, Goldhirsch A, Dyer MJS. Expression of BCL-2 in primary breast cancer and its correlation with tumour phenotype. *Ann Oncol* 5:409-414, 1994. (Trials I-IV)
 15. Gusterson BA, Taylor CW, Price KN, Gelber RD, Säve-Söderbergh J, Anbazhagan R, et al. Prognostic value of Helix Pomatia in breast cancer. *Br J Cancer* 68:146-150, 1993. (Trial V)
 16. Gusterson BA, Gelber RD, Goldhirsch A., Price KN, Säve-Söderbergh J, Anbazhagan R, Styles K, Rudenstam C-M, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Bürki K, Castiglione M, Collins J, Lindtner J, Senn HJ for the International Breast Cancer Study Group: Prognostic importance of c-erbB-2 expression in breast cancer. *J Clin Oncol* 10:1049-1056, 1992. (Trial V)
 17. Hedley DW, Rugg CA, Gelber RD, for the Ludwig Breast Cancer Study Group: Association of DNA index and S-phase fraction with prognosis of N+ early breast cancer. *Cancer Res* 47:4729-4735, 1987. (Trials I-IV)
 18. Davis B, Zava DT, Locher G, Goldhirsch A, Hartman WH: Receptor heterogeneity of human breast cancer as measured by multiple intratumoral assays of estrogen and progesterone receptor. *Eur J Cancer Clin Oncol* 20:375-382, 1984. (Trials I-IV)
 19. Jordan VC, Zava DT, Eppenberger U, Kiser A, Sebeck S, Dowdle E, Krozowski Z, Bennett RC, Funder J, Holdaway IM, Wittliff JL. Reliability of steroid hormone receptor assays: an international study. *Eur J Cancer Clin Oncol* 19:357-363, 1983. (Trials I-IV)
 20. Zava DT, Wyler-Von Ballmoos A, Goldhirsch A, Roos W, Takahashi A, Eppenberger U, Arrenbrecht S, Martz G, Losa G, Gomez F and Guelpa C: A quality control study to assess the inter-laboratory variability of routine estrogen and progesterone receptor assays. *Eur J Cancer Clin Oncol* 18:713-721, 1982. (Trials I-IV)